JP2022151429A - Agents for treating pancreatitis - Google Patents
Agents for treating pancreatitis Download PDFInfo
- Publication number
- JP2022151429A JP2022151429A JP2021081953A JP2021081953A JP2022151429A JP 2022151429 A JP2022151429 A JP 2022151429A JP 2021081953 A JP2021081953 A JP 2021081953A JP 2021081953 A JP2021081953 A JP 2021081953A JP 2022151429 A JP2022151429 A JP 2022151429A
- Authority
- JP
- Japan
- Prior art keywords
- pancreatitis
- agent
- rna
- treating pancreatitis
- denaturing agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
本発明は、膵炎治療薬に関する。The present invention relates to therapeutic agents for pancreatitis.
膵炎を根本的に治療する薬がない。There is no drug that can cure pancreatitis.
膵炎治療薬を提供することを目的とする。The purpose is to provide a therapeutic agent for pancreatitis.
本発明の目的を達成するため、次の構成を採用する。
膵炎とは、何らかの原因で膵臓の慢性的な炎症が続く病気ことで、原因の一つには、細菌やウイルスが膵臓内に侵入することで炎症を発症する。
変性剤を人体に投入することにより、膵炎の原因である身体に侵入した細菌やウイルスのＤＮＡとＲＮＡを壊すことにより増殖を防ぎ、膵炎の治療をする。
細菌やウイルスなど腎炎の病原体は、核酸を持っている。
核酸とは、ＤＮＡとＲＮＡのことである。
ＤＮＡとＲＮＡは塩基間で水素結合しているが、変性剤を加えてアルカリ性にすると、水素イオンを放出するため変性し、ＤＮＡとＲＮＡの塩基間の水素結合が壊れる。
変性剤を加えてＤＮＡとＲＮＡを壊すことにより、細菌やウイルスの増殖を防ぐことができるため、変性剤という膵炎治療薬となる。
膵炎の部分を標的とする変性剤を有効成分とするリポソーム医薬品として、人体に投与する方法もある。In order to achieve the object of the present invention, the following configuration is adopted.
Pancreatitis is a disease in which chronic inflammation of the pancreas continues for some reason. One of the causes is the onset of inflammation when bacteria or viruses enter the pancreas.
By injecting a denaturing agent into the human body, the DNA and RNA of bacteria and viruses that have invaded the body causing pancreatitis are destroyed, thereby preventing their proliferation and treating pancreatitis.
Pathogens of nephritis, such as bacteria and viruses, have nucleic acids.
Nucleic acids refer to DNA and RNA.
DNA and RNA are hydrogen-bonded between bases, but when a denaturing agent is added to make them alkaline, they release hydrogen ions and denature, breaking the hydrogen bond between bases of DNA and RNA.
By adding a denaturing agent to destroy DNA and RNA, it is possible to prevent the growth of bacteria and viruses, so it becomes a pancreatitis therapeutic agent called a denaturing agent.
There is also a method of administering to the human body as a liposome drug containing, as an active ingredient, a denaturing agent that targets the pancreatitis.
変性剤という膵炎の治療薬を人体に投与することにより、膵炎を治療する。
代表的な変性剤は、尿素薬がある。Pancreatitis is treated by administering a therapeutic agent for pancreatitis called a denaturing agent to the human body.
A representative denaturant is a urea drug.
変性剤という膵炎の治療薬を手術により、膵臓に注入する。
膵臓を標的とする変性剤を有効成分とするリポソーム医薬品として、飲み薬として飲むか、注射により投与する。
代表的な変性剤は、尿素薬がある。A treatment for pancreatitis called a denaturant is surgically injected into the pancreas.
As a liposome drug containing a degenerative agent that targets the pancreas as an active ingredient, it is taken orally or administered by injection.
A representative denaturant is a urea drug.
特願２０２０－１５５８６２Patent application 2020-155862
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021081953A JP2022151429A (en) | 2021-03-26 | 2021-03-26 | Agents for treating pancreatitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021081953A JP2022151429A (en) | 2021-03-26 | 2021-03-26 | Agents for treating pancreatitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2022151429A true JP2022151429A (en) | 2022-10-07 |
Family
ID=83464254
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021081953A Pending JP2022151429A (en) | 2021-03-26 | 2021-03-26 | Agents for treating pancreatitis |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2022151429A (en) |
-
2021
- 2021-03-26 JP JP2021081953A patent/JP2022151429A/en active Pending
Non-Patent Citations (3)
| Title |
|---|
| BIOCHEMISTRY, vol. 2, no. 1, JPN6021028384, 1963, pages 168 - 175, ISSN: 0004828136 * |
| 福井県衛生環境研究センター年報, vol. 13, JPN6021028380, 2014, pages 99 - 101, ISSN: 0004828137 * |
| 薬学雑誌, vol. 87, no. 8, JPN6021028385, 1967, pages 1006 - 1009, ISSN: 0004828135 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Giuliani et al. | Effective combination of minocycline and interferon-β in a model of multiple sclerosis | |
| Monassier | Reperfusion injury in acute myocardial infarction. From bench to cath lab. Part I: Basic considerations | |
| WO2000051623A2 (en) | Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide-induced clinical conditions | |
| US10463690B2 (en) | Method and compositions for treating cancerous tumors | |
| Di Emidio et al. | CAR-T cell therapy causes inflammation by IL-1 which activates inflammatory cytokine mast cells: antiinflammatory role of IL-37 | |
| AR119430A1 (en) | METHODS TO TREAT OR PREVENT SPINAL MUSCULAR ATROPHY | |
| MX2023007609A (en) | Methods of enhancing non-viral gene therapy. | |
| JP2023053338A5 (en) | ||
| Wang et al. | Role of adenosine kinase inhibitor in adenosine augmentation therapy for epilepsy: a potential novel drug for epilepsy | |
| JP2022151429A (en) | Agents for treating pancreatitis | |
| Cooke et al. | Future impact of mRNA therapy on cardiovascular diseases | |
| JP2022151430A (en) | Agents for treating cholecystitis | |
| JP2022151436A (en) | Agents for treating meningitidis and encephalitis | |
| JP2022151437A (en) | Agents for treating retinitis | |
| JP2022151433A (en) | Agents for treating cystitis | |
| JP2022151428A (en) | Agent for treating nephritis | |
| JP2022151432A (en) | Agents for treating myocarditis and pericarditis | |
| JP2022151439A (en) | Agents for treating rhinitis | |
| JP2022151427A (en) | Agents for treating esophagitis | |
| JP2022151440A (en) | Agents for treating arthritis | |
| JP2022151438A (en) | Agents for treating conchitis and tympanitis | |
| WO2004024089A3 (en) | Inhibition or activation of adam9 and adam15 for treatment of vascularization-related disease and wound healing | |
| JP2022146830A (en) | Therapeutic agent for retinal detachment | |
| JP2022151431A (en) | Agent for treating enteritis | |
| JP2022124985A (en) | Pneumonia therapeutic drugs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20210326 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210817 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20220719 |